COVID-19 in persons with chronic myeloid leukaemia.
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
Betacoronavirus
/ pathogenicity
COVID-19
Child
China
/ epidemiology
Coronavirus Infections
/ complications
Disease Progression
Female
Humans
Imatinib Mesylate
/ therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ complications
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ complications
Prevalence
Protein Kinase Inhibitors
/ therapeutic use
Risk Factors
SARS-CoV-2
Surveys and Questionnaires
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
12
04
2020
accepted:
27
04
2020
revised:
23
04
2020
pubmed:
20
5
2020
medline:
15
7
2020
entrez:
20
5
2020
Statut:
ppublish
Résumé
We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of COVID-19 in our subjects, 0.9% (95% Confidence Interval, 0.1, 1.8%) was ninefold higher than 0.1% (0, 0.12%) reported in normals but lower than 10% (6, 17%) reported in hospitalised persons with other haematological cancers or normal health-care providers, 7% (4, 12%). Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024). There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096). Other co-variates such as age and TKI-therapy duration were not significantly associated with an increased risk of developing COVID-19. Persons with these risk factors may benefit from increased surveillance of SARS-CoV-2 infection and possible protective isolation.
Identifiants
pubmed: 32424293
doi: 10.1038/s41375-020-0853-6
pii: 10.1038/s41375-020-0853-6
pmc: PMC7233329
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Imatinib Mesylate
8A1O1M485B
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1799-1804Investigateurs
Yicheng Zhang
(Y)
Weiming Li
(W)
Yang Chao
(Y)
Jingming Guo
(J)
Guolin Yuan
(G)
Zhuangzhi Yang
(Z)
Shiming Chen
(S)
Chucheng Wan
(C)
Wei Chang
(W)
Hui Cheng
(H)
Youshan Zhang
(Y)
Jun Qin
(J)
Xuelan Zuo
(X)
Daozi Jiang
(D)
Hongxiang Wang
(H)
Jun Huang
(J)
Youfang Zhao
(Y)
None Bin Chen
Qing Wu
(Q)
Zhiping Huang
(Z)
Qihuan Liu
(Q)
Ying Bao
(Y)
Dalin Zhang
(D)
Xinhua Zhang
(X)
Zhe Zhao
(Z)
Renying Ge
(R)
Jie Du
(J)
Hongbo Ren
(H)
Hong Han
(H)
Yunhui Wei
(Y)
Hang Xiang
(H)
Commentaires et corrections
Type : CommentIn
Références
Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7.
doi: 10.1016/S1470-2045(20)30096-6
Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020:S0923-7534(20)36383-3.
Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21:e180.
doi: 10.1016/S1470-2045(20)30150-9
Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21:e181.
doi: 10.1016/S1470-2045(20)30149-2
Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 2020. https://doi.org/10.1001/jamaoncol.2020.0980 .
Kutikov A, Weinberg DS, Edelman MJ, Horwitz EM, Uzzo RG, Fisher RI. A war on two fronts: cancer care in the time of COVID-19. Ann Intern Med. 2020. https://doi.org/10.7326/M20-1133 .
The Lancet Oncology. COVID-19: global consequences for oncology. Lancet Oncol. 2020;21:467.
doi: 10.1016/S1470-2045(20)30175-3
Lilienfeld-Toal M, Vehreschild JJ, Cornely O, Pagano L, Compagno F, EHA Infectious Disease Scientific Working Group, et al. Frequently asked questions regarding SARS-CoV2 in cancer patients—recommendations for clinicians caring for patients with malignant diseases. Leukemia. 2020. In press.
He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;1–9. https://doi.org/10.1038/s41375-020-0836-7 .
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.
doi: 10.1038/s41375-020-0776-2
Gale RP, Opelz G. Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much. Leuk Res. 2017;57:109–11.
doi: 10.1016/j.leukres.2017.03.003
Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008;14:2484–91.
doi: 10.1158/1078-0432.CCR-07-4393
Thiant S, Moutuou MM, Laflamme P, Sidi Boumedine R, Leboeuf DM, Busque L, et al. Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients. Blood Cancer J. 2017;7:e551.
doi: 10.1038/bcj.2017.29
Dörfel D, Lechner CJ, Joas S, Funk T, Gutknecht M, Salih J, et al. The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells. Cancer Immunol Immunother. 2018;67:775–83.
doi: 10.1007/s00262-018-2129-9
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2002032 .
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
doi: 10.1016/S0140-6736(20)30211-7
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
doi: 10.1016/S0140-6736(20)30183-5
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72/314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. https://doi.org/10.1001/jama.2020.2648 .
Spychalski P, Błażyńska-Spychalska A, Kobiela J. Estimating case fatality rates of COVID-19. Lancet Infect Dis. 2020:S1473-3099(20)30246–2.